Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy
- VernacularTitle:非奈利酮联合标准方案治疗糖尿病肾病的药物经济学评价
- Author:
Hai LIANG
1
;
Runan XIA
1
;
Panpan DI
1
;
Mengmeng ZHAO
1
;
Pengcheng ZHANG
1
;
Yashen HOU
1
;
Hong ZHANG
1
;
Wei WU
1
;
Miao YANG
1
Author Information
1. Dept. of Pharmacy，the People’s Hospital of Bozhou，Anhui Bozhou 236800，China
- Publication Type:Journal Article
- Keywords:
finerenone;
diabetic nephropathy;
cost-utility;
Markov model;
pharmacoeconomics
- From:
China Pharmacy
2025;36(1):86-90
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy （DN）. METHODS From the perspective of healthcare service providers， a Markov model was established to simulate the dynamic changes of each stage in DN patients who received finerenone combined with the standard treatment regimen or the standard treatment regimen alone based on the phase Ⅲ clinical trial study of finerenone for DN. Markov model was used to perform the cost-effectiveness of long-term effects and the costs of the two therapies with a simulation cycle of 4 months， a simulation period of 15 years and an annual discount rate of 5%. At the same time， one-way sensitivity analysis and probability sensitivity analysis were performed， and the stability of the results was validated. RESULTS Accumulative cost of the standard treatment regimen was 579 329.54 yuan， and the accumulative utility was 8.052 4 quality-adjusted life year （QALYs）； the accumulative cost of finerenone combined with the standard treatment regimen was 332 520.61 yuan， and the accumulative utility was 8.187 4 QALYs. Finerenone combined with the standard treatment regimen was more cost-effective. The results of one-way sensitivity analysis showed that dialysis status utility value， DN stage 3 utility value and DN stage 4 utility value had a great influence on the incremental cost-effectiveness ratio， but did not affect the robustness of the model. The results of probability sensitivity analysis showed that finerenone combined with the standard treatment regimen was more cost-effective with 100% probability. CONCLUSIONS For DN patients， finerenone combined with the standard treatment regimen is more cost-effective as an absolute advantage option.
